Neovacs, a leading biotechnology company in the development of anti-cytokine and anti-protein viral regulation therapeutic vaccines to treat certain cancers and inflammatory diseases, announced that it had begun a phase I/II clinical study at three study centres in South Africa with the candidate TNF
Navigation
Daily News
- Are Cities Designed For Women? Penn-ICOWHI Conference Examines Urban Women’s Health
- Stimuvax Will Become Decision Resources’ Proprietary Clinical Gold Standard For The Treatment Of Locally Advanced Non-Small-Cell Lung Cancer
- Researchers Develop Tool To Help Study Prostate Cancer
- Seeking ‘Next Generation’ Treatment For Breast Cancer
- New Plavix Warning: Lack of Effect in Many People
Translator
 |  |  |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  | ||
| By N2H | |||||||||